UY33183A - Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento - Google Patents

Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento

Info

Publication number
UY33183A
UY33183A UY0001033183A UY33183A UY33183A UY 33183 A UY33183 A UY 33183A UY 0001033183 A UY0001033183 A UY 0001033183A UY 33183 A UY33183 A UY 33183A UY 33183 A UY33183 A UY 33183A
Authority
UY
Uruguay
Prior art keywords
manufacture
pharmaceutical composition
medicinal product
inhibiting compounds
compounds
Prior art date
Application number
UY0001033183A
Other languages
English (en)
Inventor
Canales Eda
Michael O Neil Hanrahan Clarke
Scott E Lazerwith
Lew Willard
Philip A Morganelli
William J Watkins
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43538203&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33183(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of UY33183A publication Critical patent/UY33183A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Se proporcionan compuestos de Fórmula I: y sales y ésteres farmacéuticamente aceptables de dichos compuestos. Los compuestos, las composiciones y los métodos proporcionados son útiles para el tratamiento de infecciones por virus Flaviviridae, en particular infecciones de hepatitis C.
UY0001033183A 2010-01-15 2011-01-14 Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento UY33183A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29557610P 2010-01-15 2010-01-15
US35348110P 2010-06-10 2010-06-10

Publications (1)

Publication Number Publication Date
UY33183A true UY33183A (es) 2011-08-31

Family

ID=43538203

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033183A UY33183A (es) 2010-01-15 2011-01-14 Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento

Country Status (27)

Country Link
US (2) US8513298B2 (es)
EP (2) EP3219713A1 (es)
JP (2) JP5868872B2 (es)
KR (1) KR101727776B1 (es)
CN (1) CN102712633B (es)
AP (1) AP3576A (es)
AR (1) AR080001A1 (es)
AU (1) AU2011205744B2 (es)
BR (1) BR112012017382A2 (es)
CA (1) CA2785567C (es)
CL (1) CL2012001960A1 (es)
CR (1) CR20120417A (es)
EA (1) EA021196B1 (es)
EC (1) ECSP12012104A (es)
ES (1) ES2626150T3 (es)
IL (1) IL220545B (es)
MX (1) MX2012008211A (es)
NZ (1) NZ600817A (es)
PE (1) PE20130281A1 (es)
PL (1) PL2523950T3 (es)
PT (1) PT2523950T (es)
SG (2) SG182475A1 (es)
SI (1) SI2523950T1 (es)
TW (1) TWI491609B (es)
UY (1) UY33183A (es)
WO (1) WO2011088345A1 (es)
ZA (1) ZA201205248B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP3409A (en) * 2009-07-21 2015-08-31 Gilead Sciences Inc Inhibitors of flaviviridae viruses
BR112012005438A2 (pt) 2009-09-09 2018-03-20 Gilead Sciences Inc inibidores de vírus flaviviridae
PE20130281A1 (es) * 2010-01-15 2013-03-08 Gilead Sciences Inc Derivados de acido 5-alquinil-3-amida-2-tiofeno-carboxilico como inhibidores del virus flaviviridae
SG182478A1 (en) 2010-01-15 2012-08-30 Gilead Sciences Inc Inhibitors of flaviviridae viruses
US20130273005A1 (en) 2010-12-20 2013-10-17 Gilead Sciences, Inc. Methods for treating hcv
DE102011003295A1 (de) * 2011-01-28 2012-08-02 Kiekert Ag Kraftfahrzeugschloss
ES2561888T3 (es) * 2011-07-13 2016-03-01 Gilead Sciences, Inc. Derivados de ácido tiofeno-2-carboxílico útiles como inhibidores de virus Flaviviridae
EP2709613B2 (en) * 2011-09-16 2020-08-12 Gilead Pharmasset LLC Methods for treating hcv
CN103087052A (zh) * 2011-10-31 2013-05-08 上海壹志医药科技有限公司 噻吩衍生物及其药物用途
WO2013185103A1 (en) 2012-06-08 2013-12-12 Gilead Sciences, Inc. Macrocyclic inhibitors of flaviviridae viruses
NZ724616A (en) 2012-06-08 2018-06-29 Gilead Sciences Inc Macrocyclic inhibitors of flaviviridae viruses
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
US8759544B2 (en) 2012-08-17 2014-06-24 Gilead Sciences, Inc. Synthesis of an antiviral compound
US8927741B2 (en) * 2012-08-17 2015-01-06 Gilead Sciences, Inc. Synthesis of an antiviral compound
US8841340B2 (en) * 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound
WO2014120981A1 (en) 2013-01-31 2014-08-07 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US10190162B2 (en) 2014-10-23 2019-01-29 Complete Genomics, Inc. Signal confinement sequencing (SCS) and nucleotide analogues for signal confinement sequencing
CA2972259A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US10328061B2 (en) 2016-05-02 2019-06-25 Florida State University Research Foundation, Inc. Treatment of Zika virus infections using alpha-glucosidase inhibitors
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
SI3464336T1 (sl) 2016-06-01 2022-06-30 Athira Pharma, Inc. Spojine
KR102626210B1 (ko) 2017-12-07 2024-01-18 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
CN108096562B (zh) * 2017-12-25 2021-05-11 武汉百药联科科技有限公司 20s蛋白酶体抑制剂在制备治疗日本乙型脑炎病毒感染的药物中的用途
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US743729A (en) * 1903-03-02 1903-11-10 William Clark Kirk Work-support for lathes.
US3533088A (en) * 1967-10-31 1970-10-06 Rca Corp Control circuit for memory
US4714839A (en) * 1986-03-27 1987-12-22 Advanced Micro Devices, Inc. Control circuit for disabling or enabling the provision of redundancy
US4721868A (en) * 1986-09-23 1988-01-26 Advanced Micro Devices, Inc. IC input circuitry programmable for realizing multiple functions from a single input
JPH02146195A (ja) * 1988-11-28 1990-06-05 Nec Corp 半導体記憶装置
JPH03214500A (ja) * 1990-01-18 1991-09-19 Sony Corp メモリ装置
JP2575919B2 (ja) * 1990-03-22 1997-01-29 株式会社東芝 半導体記憶装置の冗長回路
US5959445A (en) * 1995-09-29 1999-09-28 Intel Corporation Static, high-sensitivity, fuse-based storage cell
US5861421A (en) 1995-12-21 1999-01-19 Smithkline Beecham Corporation 4,4-(disubstituted) cyclohexan-1-one monomers and related compounds
US6037799A (en) * 1995-12-29 2000-03-14 Stmicroelectronics, Inc. Circuit and method for selecting a signal
US20050119332A1 (en) 1998-03-12 2005-06-02 Lone Jeppesen Substituted thiophene compounds as modulators of protein tyrosine phosphatases (PTPases)
US20020002199A1 (en) 1998-03-12 2002-01-03 Lone Jeppesen Modulators of protein tyrosine phosphatases (ptpases)
US6175261B1 (en) * 1999-01-07 2001-01-16 Texas Instruments Incorporated Fuse cell for on-chip trimming
US6275063B1 (en) * 1999-08-24 2001-08-14 Micron Technology, Inc. Method and apparatus for limited reprogrammability of fuse options using one-time programmable elements
US6353336B1 (en) * 2000-03-24 2002-03-05 Cypress Semiconductor Corp. Electrical ID method for output driver
DK1401825T3 (da) 2001-06-11 2009-11-09 Virochem Pharma Inc Thiophenderivater som antivirale midler mod flavivirus-infektion
EP1395571A1 (en) 2001-06-11 2004-03-10 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
KR100481179B1 (ko) * 2002-09-10 2005-04-07 삼성전자주식회사 퓨즈를 구비한 회로 및 이를 이용한 반도체 장치
JP3884374B2 (ja) * 2002-12-06 2007-02-21 株式会社東芝 半導体装置
ES2345438T3 (es) * 2002-12-10 2010-09-23 Virochem Pharma Inc. Compuestos y metodos para el tratamiento o prevencion de infecciones por flavivirus.
DK1569929T3 (da) 2002-12-10 2010-08-16 Virochem Pharma Inc Forbindelser og fremgangsmåder til behandling eller forebyggelse af flavi-virusinfektioner
KR100569585B1 (ko) * 2003-12-05 2006-04-10 주식회사 하이닉스반도체 내부 전원 드라이버 제어 회로
DE10359791A1 (de) 2003-12-19 2005-07-21 Bayer Healthcare Ag Substituierte Thiophene
US7521473B2 (en) 2004-02-25 2009-04-21 Wyeth Inhibitors of protein tyrosine phosphatase 1B
EP1732919A1 (en) * 2004-03-30 2006-12-20 Chiron Corporation Substituted thiophene derivatives as anti-cancer agents
DE102004061746A1 (de) 2004-12-22 2006-07-06 Bayer Healthcare Ag Alkinyl-substituierte Thiophene
DE102005028077A1 (de) 2004-12-22 2006-07-13 Aicuris Gmbh & Co. Kg Alkinyl-substituierte Thiophene
KR20080016597A (ko) 2005-05-13 2008-02-21 바이로켐 파마 인코포레이티드 플라비바이러스 감염의 예방 또는 치료용 화합물 및 그의예방 또는 치료 방법
EP1910565A4 (en) 2005-07-07 2009-10-28 Athlomics Pty Ltd POLYNUCLEOTIDE MARKER GENES AND THEIR EXPRESSION IN THE DIAGNOSIS OF ENDOTOXEMIA
GB0602046D0 (en) 2006-02-01 2006-03-15 Smithkline Beecham Corp Compounds
JP2009526794A (ja) 2006-02-15 2009-07-23 サノフィ−アベンティス 新規なアミノアルコール置換アリールチエノピリミジノン、それらの製造方法及び薬剤としてそれらの使用
AP2579A (en) * 2006-11-15 2013-01-29 Virochem Pharma Inc Thiophene analogues for the treatment or prevention of flavivirus infections
JP2010510191A (ja) 2006-11-17 2010-04-02 スミスクライン ビーチャム コーポレーション 抗ウイルス剤としての２−カルボキシチオフェン誘導体
SG171890A1 (en) 2008-12-03 2011-07-28 Presidio Pharmaceuticals Inc Inhibitors of hcv ns5a
AP3409A (en) 2009-07-21 2015-08-31 Gilead Sciences Inc Inhibitors of flaviviridae viruses
BR112012005438A2 (pt) 2009-09-09 2018-03-20 Gilead Sciences Inc inibidores de vírus flaviviridae
CA2781614A1 (en) 2009-11-25 2011-06-09 Vertex Pharmaceuticals Incorporated 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections
SG182478A1 (en) * 2010-01-15 2012-08-30 Gilead Sciences Inc Inhibitors of flaviviridae viruses
PE20130281A1 (es) * 2010-01-15 2013-03-08 Gilead Sciences Inc Derivados de acido 5-alquinil-3-amida-2-tiofeno-carboxilico como inhibidores del virus flaviviridae
JP2013529684A (ja) 2010-06-28 2013-07-22 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染の処置または予防のための化合物および方法
ES2561888T3 (es) 2011-07-13 2016-03-01 Gilead Sciences, Inc. Derivados de ácido tiofeno-2-carboxílico útiles como inhibidores de virus Flaviviridae

Also Published As

Publication number Publication date
KR101727776B1 (ko) 2017-04-17
EP2523950B1 (en) 2017-03-15
ZA201205248B (en) 2013-03-27
CA2785567C (en) 2018-03-27
SG10201500298PA (en) 2015-03-30
EA021196B1 (ru) 2015-04-30
JP5868872B2 (ja) 2016-02-24
EP2523950A1 (en) 2012-11-21
US9321753B2 (en) 2016-04-26
US20130315861A1 (en) 2013-11-28
AU2011205744B2 (en) 2015-06-25
AR080001A1 (es) 2012-03-07
PT2523950T (pt) 2017-06-01
CN102712633A (zh) 2012-10-03
ES2626150T3 (es) 2017-07-24
PE20130281A1 (es) 2013-03-08
US8513298B2 (en) 2013-08-20
NZ600817A (en) 2014-08-29
IL220545B (en) 2018-02-28
JP2016041732A (ja) 2016-03-31
EA201290576A1 (ru) 2013-01-30
TWI491609B (zh) 2015-07-11
AP3576A (en) 2016-02-08
JP2013517291A (ja) 2013-05-16
CL2012001960A1 (es) 2012-10-26
BR112012017382A2 (pt) 2017-12-05
MX2012008211A (es) 2012-08-08
CA2785567A1 (en) 2011-07-21
PL2523950T3 (pl) 2017-09-29
CR20120417A (es) 2012-11-30
US20110178129A1 (en) 2011-07-21
EP3219713A1 (en) 2017-09-20
KR20120101733A (ko) 2012-09-14
SG182475A1 (en) 2012-08-30
WO2011088345A1 (en) 2011-07-21
AU2011205744A1 (en) 2012-07-26
SI2523950T1 (sl) 2017-06-30
TW201134822A (en) 2011-10-16
AP2012006414A0 (en) 2012-08-31
CN102712633B (zh) 2015-07-29
ECSP12012104A (es) 2012-09-28
IL220545A0 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
UY33775A (es) Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos
ECSP12012103A (es) Inhibidores de virus flaviviridae.
UY32793A (es) Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos
SV2010003451A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
CO7240410A2 (es) Inhibidores macrocíclicos de virus flaviviridae
ECSP15000435A (es) Inhibidores macrocíclicos de virus flaviviridae
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
CU20140068A7 (es) Triazolopiridinas sustituidas
DOP2010000259A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211
UY35210A (es) Inhibidores de autotaxina
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
ECSP13013011A (es) Triazolopiridinas
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
CU20120171A7 (es) Triazolopiridinas sustituidas
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CL2014001016A1 (es) Compuestos triciclicos condensados y sus sales farmaceuticamente aceptables; composicion farmaceutica que los comprende; y su uso en el tratamiento de una infeccion viral.
CU20140037A7 (es) Derivados de estra- 1,3,5(10), 16- tetraen- 3- carboximida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
UY31864A (es) Derivados de urea hetericíclica y métodos de uso de los mismos-332
UY32316A (es) Derivados de piperidina utiles en el tratamiento de infecciones bacterianas
UY33745A (es) Derivados de difenilamina: usos, procedimiento de síntesis y composiciones farmacéuticas
AR086876A1 (es) Derivados heterociclicos de sulfonamida
UY33806A (es) ?compuestos novedosos de imidazoquinolina, composiciones que los contienen y su uso en el tratamiento de enfermedades mediadas por tlr7?

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20191121